Here‚Äôs a **comprehensive scientific summary** of what is known *from published research (preclinical and early mechanistic studies)* about the **peptide ‚ÄúA-11‚Äù** (often described as an ANXA1-derived or angiopoietin-interacting peptide). Unfortunately, there are **no established clinical pharmacokinetics, human half-life or approved dosing regimens** because this peptide has **not been developed as a regulated drug** ‚Äî only investigated in research settings. Therefore, most parameters like oral bioavailability, human half-life, safe dose range, or minimum effective dose **are not defined in humans**.

---

## üß¨ 1. **Identity & Mechanism (Pharmacological Actions)**

**A11 Peptide**

* A short peptide (11 amino acids) derived from **Annexin A1 (ANXA1)** or identified from angiopoietin segments, depending on context. ([biocat.com][1])

**Primary reported actions (preclinical):**

1. **Anti-angiogenic activity**

   * Binds to angiopoietins and **inhibits Ang-2 binding to the Tie2 receptor**, reducing endothelial cell migration and vessel formation. ([PubMed][2])

2. **Tumor vascular inhibition / reduced vascular density**

   * Demonstrated in tumour and retinal neovascularization animal models. ([PubMed][2])

3. **Inhibition of EphA2/ANXA1 interaction**

   * Blocks ANXA1 attachment to EphA2, increases EphA2 ubiquitination, internalization and degradation, suppressing nasopharyngeal carcinoma cell proliferation, migration, invasion and angiogenesis. ([biocat.com][1])

4. **Reduced tumour immune evasion via PD-L1 degradation**

   * Binds PD-L1, enhances its ubiquitination and degradation ‚Äî boosting T-cell anti-tumour activity (in vitro & mouse studies). ([PubMed][3])

5. **Enhanced radiosensitivity in tumours**

   * Decreases EphA2 signalling related to radioresistance (preclinical). ([PubMed][4])

üí° **Mechanistic summary:**
A11 modulates key signalling pathways including Ang-Tie2, EphA2, and PD-L1/USP7, affecting angiogenesis, tumour cell survival, immune response and potentially sensitivity to therapies. All evidence so far is from **cell and animal models**. ([PubMed][2])

---

## üìä 2. **Pharmacologic Metrics (Time-Linked Effects)**

**Time courses and kinetic data from published research are scarce and mostly qualitative:**

* There are **no human half-life measurements published** for A11.
* Typical results in vitro/in vivo show **activity measured over hours to days** in angiogenesis assays and tumor suppression models. ([PubMed][2])

**Experimental time frames reported (examples):**

* In anti-angiogenic assays, effects were measurable within **hours to days** in cells or chick/mouse models. ([PubMed][2])
* Tumour volume reduction observed over **weeks in xenograft models**. ([PubMed][2])

**Inferences on peptide stability:**

* Unmodified small peptides generally have **short plasma half-lives (minutes to hours)** due to rapid proteolysis and renal clearance unless modified or delivered via a protected vehicle, based on general peptide pharmacology principles. ([peptiderecon.com][5])

üß™ *But specifically for A11,* no peer-reviewed half-life or plasma stability data have been published.

---

## üìà 3. **Bioavailability & Routes of Administration**

There are **no published clinical studies** reporting:

* oral bioavailability
* subcutaneous or intravenous bioavailability
* human pharmacokinetic profiles

**General peptide pharmacology context (not specific to A11):**
Therapeutic peptides are usually:

* **poorly bioavailable orally** due to degradation in the GI tract,
* typically administered **parenterally** (e.g., subcutaneous or intravenous),
* and can have **substantial variability in absorption and half-life** without modification. ([peptiderecon.com][5])

So, **oral bioavailability of native A11 is likely very low** and not characterized.

---

## üíä 4. **Dosage & Safety**

There are **no approved or standard clinical doses** for A11. All investigations are **preclinical**, typically using:

* **micromolar concentrations in cell cultures**,
* **mg/kg ranges in animal models** (not systematically documented).

Safety data are generally **only from animal models or in vitro**. No formal toxicology, safe range or maximum tolerated dose has been defined in humans.

---

## üìå 5. **Known Research Data Summary**

| Parameter                          | Known Status                      | Numbers / Notes                                                                                 |
| ---------------------------------- | --------------------------------- | ----------------------------------------------------------------------------------------------- |
| **Pharmacological actions**        | Documented in preclinical studies | Anti-angiogenic; EphA2 modulation; PD-L1 degradation; immune response enhancement ([PubMed][2]) |
| **Half-life (human)**              | **Not reported**                  | Inferred short (minutes‚Äìhours typical for peptides) ([peptiderecon.com][5])                     |
| **Bioavailability (oral)**         | **Not established**               | Most small peptides poorly orally bioavailable ([peptiderecon.com][5])                          |
| **Routes studied**                 | Preclinical                       | Likely parenteral/formulation delivery in animal models                                         |
| **Dosage (animal/experimental)**   | Varies widely; not standardized   | No definitive mg/kg or ¬µmol/kg public consensus                                                 |
| **Safe range (human)**             | **Not defined**                   | No clinical trials                                                                              |
| **Minimum effective dose (human)** | **Not defined**                   | Only preclinical, context-specific activity                                                     |

---

## ‚ö†Ô∏è Key Limitations

1. **No clinical pharmacokinetics or dosing approved**

   * All available A11 information comes from **research settings**, not pharmaceutical development.

2. **No human safety or regulatory data**

3. **No standardized potency or effectiveness studies across models**

4. **Terminology confusion**

   * ‚ÄúA11‚Äù may refer to different peptides in different research contexts (e.g., ANXA1-derived versus angiopoietin-derived) ‚Äî these are mechanistically distinct. ([PubMed][2])

---

## üß† Summary

| Category                               | Status                                                |
| -------------------------------------- | ----------------------------------------------------- |
| Pharmacological actions                | Yes ‚Äî anti-angiogenesis, tumour signalling modulation |
| Half-life (human)                      | Not available                                         |
| Bioavailability (oral or other routes) | Not available                                         |
| Human dose range                       | Not available                                         |
| Safe range & minimum effective dose    | Not available                                         |

---

If you want, I can help **interpret a specific study** on A11 (e.g., provide detailed data from a publication PDF), or help **compare A11 with other peptides** that *do* have defined clinical data.

[1]: https://www.biocat.com/products/a11-tp2685-10mg-tm?utm_source=chatgpt.com "A11"
[2]: https://pubmed.ncbi.nlm.nih.gov/21943108/?utm_source=chatgpt.com "A novel angiopoietin-derived peptide displays anti-angiogenic activity and inhibits tumour-induced and retinal neovascularization - PubMed"
[3]: https://pubmed.ncbi.nlm.nih.gov/37001908/?utm_source=chatgpt.com "ANXA1-derived peptide for targeting PD-L1 degradation ..."
[4]: https://pubmed.ncbi.nlm.nih.gov/41387202/?utm_source=chatgpt.com "A11 Peptide Enhances Radiosensitivity by Degrading ..."
[5]: https://peptiderecon.com/intel-mechanisms?utm_source=chatgpt.com "INTEL REPORT: Comparative Mechanisms of Action in Therapeutic Peptides | Peptide Recon"
